Gentler combo therapy tested for rare lymphoma
NCT ID NCT06583837
Summary
This study is testing a new first treatment for early-stage MALT lymphoma, a type of slow-growing cancer. It combines a targeted drug (orelabrutinib) with a very low dose of radiation, aiming to control the disease effectively while minimizing side effects. The trial will enroll 50 adults to see how well this approach works and how safe it is over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL MARGINAL ZONE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.